Value Plus

Arihant's Value Plus – November 2017

Market Outlook November: Going ahead, Indian equity markets are in a bull phase and look positive. Government is not leaving any stone unturned to bring the economy on track. The mega announcement on bank recapitalization will strengthen banks which will lead to more jobs, more growth and encourage investment. Market participants will closely watch GST council meeting, implementation of bank recapitalization and road building programme. Apart from this, Q2FY18 ongoing corporate earnings, US FOMC meeting, BOE monetary policy, BOJ monetary Policy, FIIs trend, currency movement and crude oil price movement are the major factors which will decide the market direction. We recommend investors to stay invested in fundamentally sound companies for long term.

In this issue:

  • Movers & Shakers
  • Market Outlook
  • Nifty Technical Outlook
  • Technical Stocks
  • Auto Sales
  • Commodity Outlook
  • Mutual Fund
  • Key Financial Events – Nov

Nifty Technical Outlook November: On the monthly chart, after two months of consolidation we are observing strong bull candle which suggests that upside momentum is likely to continue. In the coming month if Nifty trades and closes above 10442 level then it is likely to test 10604 – 10765 – 10954 levels. However, if Nifty trades and closes below 10227 level then it can test 10066 – 9905 – 9717 levels.

Broadly, we are of the opinion that for current month 9905 remains strong support for the markets. Hence, as long as Nifty holds this mentioned level we are of the opinion that Nifty may test 10700 – 10900 levels in couple of months.

Tags: Technical StocksAuto SalesKey EventsMutual FundMovers & ShakersCommodity OutlookMarket OutlookNifty Technical OutlookCadila Healthcare RECSoybean

Arihant's November Investment Newsletter is now available #‎ValuePlus
Click here to go through our flipbook now.
Click here to download full pdf report.

Search Reports



Daily Metal & Agro Buzz

HIGHLIGHTS: Natural gas...

Read More

Daily Market Update...

On 22/03/2018 markets opened...

Read More

Daily Metal & Agro Buzz:

HIGHLIGHTS: Cane arrears of...

Read More

Daily Currency Market...

HIGHLIGHTS: The dollar fell...

Read More

Daily Market Update...

On 21/03/2018 markets opened...

Read More



Read More



Read More

Century Textile

We have valued each segment...

Read More



Read More

Ajanta Pharma Initiating...

Ajanta Pharma (AJP) delivered...

Read More

Subscribe to newsletter

Request a call back

DISCLAIMER: This document has been prepared by Arihant Capital Markets Limited (hereinafter called as Arihant) and its subsidiaries and associated companies. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. Arihant Capital Markets Ltd (including its affiliates) or its officers, directors, personnel and employees, including persons involved in the preparation or issuance of this material may; (a) from time to time, have positions in, and buy or sell or (b) be engaged in any other transaction and earn brokerage or other compensation in the financial instruments/products discussed herein or act as advisor or lender/borrower in respect of such securities/financial instruments/products or have other potential conflict of interest with respect to any recommendation and related information and opinions.